G. Steven Burrill

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for more than 40 years. Mr. Burrill founded and has been Chief Executive Officer of Burrill & Company, a venture capital and merchant banking firm, since 1994. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the field of biotechnology, life sciences, high technology, and manufacturing worldwide. He currently serves on the Boards of Directors of AliveCor (Chairman), Catalyst Biosciences, Depomed (NASDAQ: DEPO), Iverson Genetics, NewBridge, Novadaq (NASDAQ: NVDQ), and XDx. Previously he served as Chairman of the Boards of BioImagene, Abunda Nutrition and Pharmasset. Mr. Burrill’s non-profit activities include serving as Chairman of the Boards of Directors of the Life Science Foundation, and the Vilas County (Wisconsin) Economic Development Corporation (VCEDC) and as Vice Chairman of the National Health Museum. He also serves on the Boards of the Bay Area Science Infrastructure Consortium, BayBio (Emeritus), The Buck Institute for Research on Aging, California Healthcare Institute (Emeritus), The Exploratorium (Emeritus), Gladstone Foundation, Kellogg Center for Biotechnology, MIT Center for Biomedical Innovation, BIO Ventures for Global Health (BVGH), and the Harvard Medical School Genetics Advisory Council. He previously served as Chairman of the Board of the National Science and Technology Medals Foundation (NSTMF) (now Emeritus), and as Chairman of Global Virus Network (GVN). He also previously chaired the National Research Council study on linkages in biotechnology between Japan and the United States and was also involved with the US-Japan Science and Technology Agreement Study of Technology Transfer Mechanisms between the US and Japan. In 2012 Mr. Burrill received the Richard Bolte, Sr. Award for Supporting Industries from the Chemical Heritage Foundation in Philadelphia for his biotechnology industry leadership worldwide. In 2011 he received a lifetime achievement award at Scrip Intelligence’s annual Scrip Award ceremony in London. That same year he received the Breath of Life Award from the Northern California Chapter of the Cystic Fibrosis Foundation to honor his contributions to the life sciences industry. In 2008 he received both the BayBio Pantheon DiNA lifetime achievement award for his biotech leadership worldwide, and the Alan Cranston Living Legend Award for his central role in advancing biomedical research globally. In 2002 he was recognized as a biotech investment visionary by the Scientific American magazine (The Scientific American 50), and was also honored that year at the American Liver Foundation’s Annual “Salute to Excellence” Gala, which honors the leaders from the Bay Area’s medical, biotech and bio-pharmaceutical industries. In 1995 Mr. Burrill received BIO’s “service award” for his global biotechnology leadership. He serves on the editorial boards of Scientific American, the Journal of Commercial Biotechnology and Life Science Leader and on the advisory boards of the Center for Policy on Emerging Technologies (C-PET) and BioAg Gateway, City of Madison. He is an advisor to the University of Illinois Institute for Genomic Biology, the University of Wisconsin-College of Agriculture and Life Sciences, the University of Minnesota College of Biological Sciences, University of California, Davis, and Duke University, and is an adjunct professor at University of California, San Francisco. He also serves on the Advisory Boards for the Department of Biology at San Francisco State University and the Biotechnology Master’s Program in the Department of Biology at the University of San Francisco. He serves on the BioNJ Diagnostics and Personalized Medicine Committee. Mr. Burrill earned a BBA degree from the University of Wisconsin, Madison.